Neuralink Implant Logs 11.32 Bits Per Second in Cursor-Control Task

Neuralink's fully implanted brain-computer interface has recorded a cursor-control throughput of 11.32 bits per second, a figure the company presents as a new record for intracortical cursor control driven by a chronically implanted device.

The number itself is the story. Bits per second is the standard information-theoretic metric used in BCI research to quantify how much intentional signal a decoder can extract from neural activity and convert into cursor movement on a screen. Higher bitrates translate directly into faster, more accurate point-and-click performance — the difference between a user laboriously selecting letters on an on-screen keyboard and approaching conversational typing speeds. The 11.32 bit/s figure sits at the upper end of what intracortical systems have reported, and Neuralink frames it as the highest cursor-control bitrate achieved to date with an implanted device.

The distinction matters for how the claim should be read. Bitrate records in the BCI literature come from different recording modalities, electrode counts, task paradigms and evaluation windows, so cross-study comparisons carry caveats. What the new figure establishes is a performance ceiling for this specific system configuration and task, evaluated under the conditions Neuralink used — not a universally benchmarked result across the field. Peer-reviewed confirmation, full methods and per-participant data will determine how the number holds up against prior intracortical results from academic groups.

For clinical neurophysiologists, the relevant technical context is well established. The Neuralink device, the N1 implant, uses 1,024 electrodes distributed across 64 threads thinner than a human hair, each threaded into the cortex by a surgical robot. An on-board chip performs spike-band signal extraction and transmits decoded data wirelessly through the skull — no percutaneous connector, no cable to a cart of amplifiers. That architecture is what separates this generation of implants from the pedestal-mounted arrays used in earlier human intracortical BCI studies, and it is the engineering reason the system can be evaluated continuously in a participant's daily environment rather than only in a lab session.

The company has been testing the device in human participants since receiving FDA clearance in 2023 to run its first-in-human trial. Participants in the trial have demonstrated cursor control, gaming and drawing tasks using decoded motor-intent signals from motor cortex. The reported bitrate record emerged from this ongoing trial program. Neuralink has also reported a second study arm focused on the Blindsight visual prosthesis, for which it received FDA breakthrough-device designation.

The measurement itself deserves attention in the reading room. Cursor-control bitrate is typically computed from a target-acquisition task: the participant moves a cursor to targets on a screen while the decoder translates neural features — in this system, spiking activity from single units and small ensembles — into two-dimensional velocity or position commands. Researchers log target selection rates, path efficiency and error rates, then collapse performance into bits per second using the standard information-transfer metric borrowed from assistive-communication research. A figure above 11 bits/s implies that a well-designed interface could, in principle, support text entry and device control at rates that approach functional daily use for people with tetraplegia or amyotrophic lateral sclerosis.

That is the clinical horizon, and it is worth stating precisely what has and has not been demonstrated. What the study program has shown, according to the company's reporting, is high-throughput cursor control in trial participants using a fully implanted, wirelessly transmitting device. What it has not yet shown publicly is durability across years in multiple participants, performance under the full range of real-world conditions, or published per-user variance — the evidence base a regulatory pathway to broad clinical use would require. The device remains investigational, operating under an FDA-cleared trial protocol rather than as a cleared commercial product.

There is also a signal-quality question that will be familiar to anyone who manages chronic intracranial recordings. Electrode-tissue interface stability determines whether single-unit yields — and therefore decoder input — persist over months. Earlier intracortical arrays showed signal degradation over time; whether the N1's thread architecture and automated signal-processing pipeline sustain the reported performance long-term is one of the central questions the trial is positioned to answer.

The 11.32 bit/s figure nonetheless marks a concrete milestone: the highest reported cursor-control throughput from a fully implanted wireless BCI, achieved in human trial participants. Whether Neuralink publishes the underlying methods and participant data, and how the system performs as implants age, will define the next phase of the clinical evidence.